Drug Delivery to the Bone Microenvironment Mediated by Exosomes: An Axiom or Enigma

References

• Boskey AL, Posner AS. Bone structure, composition, and mineralization. Orthop Clin North Am. 1984;15(4):597–612. doi:10.1016/S0030-5898(20)31258-X
   PubMedGoogle Scholar
• Buckwalter JA, Cooper RR. Bone structure and function. Instr Course Lect. 1987;36:27–48.
   PubMedGoogle Scholar
• Shea JE, Miller SC. Skeletal function and structure: implications for tissue-targeted therapeutics. Adv Drug Deliv Rev. 2005;57(7):945–957. doi:10.1016/j.addr.2004.12.017
   PubMedGoogle Scholar
• Weiner S, Wagner HD. THE MATERIAL BONE: structure-Mechanical Function Relations. Adv Musculoskeletal Dis. 1998;28(1):271–298.
   Google Scholar
• Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simões MJ, Cerri PS. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int. 2015;2015:421746. doi:10.1155/2015/421746
   PubMed Web of Science ®Google Scholar
• Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231–1234. doi:10.1038/nm.2452
   PubMed Web of Science ®Google Scholar
• Rodan GA. Bone homeostasis. Proce Nat Acad Sci United States Am. 1998;95(23):13361–13362. doi:10.1073/pnas.95.23.13361
   PubMed Web of Science ®Google Scholar
• Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–192. doi:10.1038/nm.3074
   PubMed Web of Science ®Google Scholar
• Demontiero O, Vidal C, Duque G. Aging and bone loss: new insights for the clinician. Therapeutic Adv Musculoskeletal Dis. 2012;4(2):61–76. doi:10.1177/1759720X11430858
   PubMedGoogle Scholar
• Duarte MP, Farias MLF, Coelho HSM, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol. 2001;16(9):1022–1027.
   PubMed Web of Science ®Google Scholar
• Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease: part IV of IV parts: the state of the bones in uremic hyperparathyroidism—The mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis. Metabolism. 1976;25(10):1157–1188. doi:10.1016/0026-0495(76)90024-x
   PubMedGoogle Scholar
• Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004;341:19–39. doi:10.1016/j.gene.2004.06.044
   PubMed Web of Science ®Google Scholar
• Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12(1):17–25. doi:10.1016/j.molmed.2005.11.007
   PubMed Web of Science ®Google Scholar
• Shoback D. Update in Osteoporosis and Metabolic Bone Disorders. J Clin Endocrinol Metab. 2007;92(3):747–753. doi:10.1210/jc.2007-0042
   PubMedGoogle Scholar
• Black DM, Rosen CJ. Postmenopausal Osteoporosis. N Eng J Med. 2016;374(3):254–262. doi:10.1056/NEJMcp1513724
   PubMed Web of Science ®Google Scholar
• Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61–66. doi:10.1038/bjc.1987.13
   PubMed Web of Science ®Google Scholar
• Picci P. Osteosarcoma (Osteogenic sarcoma). Orphanet J Rare Dis. 2007;2(1):6. doi:10.1186/1750-1172-2-6
   PubMedGoogle Scholar
• Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8(11):656–664. doi:10.1038/nrrheum.2012.153
   PubMed Web of Science ®Google Scholar
• Kravets I. Paget’s Disease of Bone: diagnosis and Treatment. Am J Med. 2018;131(11):1298–1303. doi:10.1016/j.amjmed.2018.04.028
   PubMedGoogle Scholar
• Rodan GA, Martin TJ. Therapeutic Approaches to Bone Diseases. Science (New York, N.Y.). 2000;289(5484):1508–1514. doi:10.1126/science.289.5484.1508
   PubMed Web of Science ®Google Scholar
• Cano A, Hermenegildo C. The endometrial effects of SERMs. Hum Reprod Update. 2000;6(3):244–254. doi:10.1093/humupd/6.3.244
   PubMedGoogle Scholar
• Brisson J, Brisson B, Coté G, Maunsell E, Bérubé S, Robert J. Tamoxifen and Mammographic Breast Densities. Cancer Epidemiol Biomarkers. 2000;9(9):911–915.
   PubMedGoogle Scholar
• Salari P, Abdollahi M. Long Term Bisphosphonate Use in Osteoporotic Patients; A Step Forward, Two Steps Back. J Pharm Pharmaceutical Sci. 2012;15(2):305–317. doi:10.18433/J3RK5J
   PubMedGoogle Scholar
• Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91(7):968–971.
   PubMed Web of Science ®Google Scholar
• Kennel KA, Drake MT. Adverse Effects of Bisphosphonates: implications for Osteoporosis Management. Mayo Clinic Proceedings. 2009;84(7):632–638. doi:10.1016/S0025-6196(11)60752-0
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates. J Bone Mineral Res. 2008;23(10):1569–1575.
   PubMed Web of Science ®Google Scholar
• Adami S, Zamberlan N. Adverse Effects of Bisphosphonates. Drug Safety. 1996;14(3):158–170. doi:10.2165/00002018-199614030-00003
   PubMed Web of Science ®Google Scholar
• Yang L, Webster TJ. Nanotechnology controlled drug delivery for treating bone diseases. Expert Opin Drug Deliv. 2009;6(8):851–864. doi:10.1517/17425240903044935
   PubMed Web of Science ®Google Scholar
• Yang X, Chen S, Liu X, Yu M, Liu X. Drug Delivery Based on Nanotechnology for Target Bone Disease. Curr Drug Deliv. 2019;16(9):782–792. doi:10.2174/1567201816666190917123948
   PubMed Web of Science ®Google Scholar
• Gu W, Wu C, Chen J, Xiao Y. Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration. Int J Nanomedicine. 2013;8:2305–2317. doi:10.2147/IJN.S44393
   PubMed Web of Science ®Google Scholar
• Ram Prasad S, Jayakrishnan A, Sampath Kumar TS. Hydroxyapatite-poly(vinyl alcohol) core-shell nanoparticles for dual delivery of methotrexate and gemcitabine for bone cancer treatment. J Drug Deliv Sci Technol. 2019;51:629–638. doi:10.1016/j.jddst.2019.03.041
   Web of Science ®Google Scholar
• Jayaraman P, Gandhimathi C, Venugopal JR, Becker DL, Ramakrishna S, Srinivasan DK. Controlled release of drugs in electrosprayed nanoparticles for bone tissue engineering. Adv Drug Deliv Rev. 2015;94:77–95. doi:10.1016/j.addr.2015.09.007
   PubMed Web of Science ®Google Scholar
• Sunoqrot S, Bugno J, Lantvit D, Burdette JE, Hong S. Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. J Controlled Release. 2014;191:115–122. doi:10.1016/j.jconrel.2014.05.006
   PubMed Web of Science ®Google Scholar
• Low SA, Kopeček J. Targeting polymer therapeutics to bone. Adv Drug Deliv Rev. 2012;64(12):1189–1204. doi:10.1016/j.addr.2012.01.012
   PubMed Web of Science ®Google Scholar
• Hengst V, Oussoren C, Kissel T, Storm G. Bone targeting potential of bisphosphonate-targeted liposomes: preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm. 2007;331(2):224–227. doi:10.1016/j.ijpharm.2006.11.024
   PubMed Web of Science ®Google Scholar
• Cole LE, Vargo-Gogola T, Roeder RK. Targeted delivery to bone and mineral deposits using bisphosphonate ligands. Adv Drug Deliv Rev. 2016;99:12–27. doi:10.1016/j.addr.2015.10.005
   PubMed Web of Science ®Google Scholar
• Ramanlal Chaudhari K, Kumar A, Megraj Khandelwal VK, et al. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. J Controlled Release. 2012;158(3):470–478. doi:10.1016/j.jconrel.2011.11.020
   PubMed Web of Science ®Google Scholar
• Hasani-Sadrabadi MM, Dashtimoghadam E, Bahlakeh G, et al. On-chip synthesis of fine-tuned bone-seeking hybrid nanoparticles. J Bone Mineral Res. 2015;10(23):3431–3449.
   Google Scholar
• Song Y-F, Liu D-Z, Cheng Y. Charge Reversible and Mitochondria/Nucleus Dual Target Lipid Hybrid Nanoparticles To Enhance Antitumor Activity of Doxorubicin. Mol Pharm. 2018;15(3):1296–1308. doi:10.1021/acs.molpharmaceut.7b01109
   PubMedGoogle Scholar
• Ortiz de Solorzano I, Alejo T, Abad M. Cleavable and thermo-responsive hybrid nanoparticles for on-demand drug delivery. J Colloid Interface Sci. 2019;533:171–181. doi:10.1016/j.jcis.2018.08.069
   PubMed Web of Science ®Google Scholar
• Park K. Facing the Truth about Nanotechnology in Drug Delivery. ACS Nano. 2013;7(9):7442–7447. doi:10.1021/nn404501g
   PubMed Web of Science ®Google Scholar
• Neuberger T, Schöpf B, Hofmann H, Hofmann M, von Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater. 2005;293(1):483–496. doi:10.1016/j.jmmm.2005.01.064
   Web of Science ®Google Scholar
• Manzoor AA, Lindner LH, Landon CD, et al. Overcoming Limitations in Nanoparticle Drug Delivery: triggered, Intravascular Release to Improve Drug Penetration into Tumors. Cancer Research. 2012;72(21):5566–5575. doi:10.1158/0008-5472.CAN-12-1683
   PubMed Web of Science ®Google Scholar
• Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75(2):193–208.
   PubMed Web of Science ®Google Scholar
• Bobrie A, Colombo M, Raposo G, Théry C. Exosome Secretion: molecular Mechanisms and Roles in Immune Responses. Traffic (Copenhagen, Denmark). 2011;12(12):1659–1668. doi:10.1111/j.1600-0854.2011.01225.x
   PubMed Web of Science ®Google Scholar
• Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochimica et Biophysica Acta. 2012;1820(7):940–948. doi:10.1016/j.bbagen.2012.03.017
   PubMed Web of Science ®Google Scholar
• Jiang L, Gu Y, Du Y, Liu J. Exosomes: diagnostic Biomarkers and Therapeutic Delivery Vehicles for Cancer. Mol Pharm. 2019;16(8):3333–3349. doi:10.1021/acs.molpharmaceut.9b00409
   PubMedGoogle Scholar
• Munson P, Shukla A. Exosomes: potential in Cancer Diagnosis and Therapy. Medicines. 2015;2(4):310–327. doi:10.3390/medicines2040310
   Google Scholar
• Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262(19):9412–9420.
   PubMed Web of Science ®Google Scholar
• Thébaud B, Stewart DJ. Exosomes. Circulation. 2012;126(22):2553–2555. doi:10.1161/CIRCULATIONAHA.112.146738
   PubMedGoogle Scholar
• Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proce Nat Acad Sci United States Am. 2010;107(14):6328–6333. doi:10.1073/pnas.0914843107
   PubMed Web of Science ®Google Scholar
• Sun D, Zhuang X, Zhang S, et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv Drug Deliv Rev. 2013;65(3):342–347. doi:10.1016/j.addr.2012.07.002
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659. doi:10.1038/ncb1596
   PubMed Web of Science ®Google Scholar
• Hurley JH, Odorizzi G. Get on the exosome bus with ALIX. Nat Cell Biol. 2012;14(7):654–655. doi:10.1038/ncb2530
   PubMedGoogle Scholar
• Anand S, Samuel M, Kumar S, Mathivanan S. Ticket to a bubble ride: cargo sorting into exosomes and extracellular vesicles. Biochimica et Biophysica Acta. 2019;1867(12):140203. doi:10.1016/j.bbapap.2019.02.005
   PubMed Web of Science ®Google Scholar
• Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17. doi:10.1038/s41556-018-0250-9
   PubMed Web of Science ®Google Scholar
• Danzer KM, Kranich LR, Ruf WP, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7(1):42. doi:10.1186/1750-1326-7-42
   PubMed Web of Science ®Google Scholar
• Tan A, Rajadas J, Seifalian AM. Exosomes as nano-theranostic delivery platforms for gene therapy. Adv Drug Deliv Rev. 2013;65(3):357–367. doi:10.1016/j.addr.2012.06.014
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Y, Li Z, Zhou K, Feng N. Exosomes as Carriers for Antitumor Therapy. ACS Biomater Sci Eng. 2019;5(10):4870–4881. doi:10.1021/acsbiomaterials.9b00417
   PubMedGoogle Scholar
• Kumar S, Michael IJ, Park J, Granick S, Cho Y-K. Cloaked Exosomes: biocompatible. Durable Degradable Encapsulation. 2018;14(34):1802052.
   Google Scholar
• Yang M, Wu SY. The Advances and Challenges in Utilizing Exosomes for Delivering Cancer Therapeutics. Front Pharmacol. 2018;9:735.
   PubMed Web of Science ®Google Scholar
• Felicetti F, De Feo A, Coscia C, et al. Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. J Transl Med. 2016;14(1):56. doi:10.1186/s12967-016-0811-2
   PubMedGoogle Scholar
• Zheng M, Huang M, Ma X, Chen H, Gao X. Harnessing Exosomes for the Development of Brain Drug Delivery Systems. Bioconjug Chem. 2019;30(4):994–1005. doi:10.1021/acs.bioconjchem.9b00085
   PubMedGoogle Scholar
• Khongkow M, Yata T, Boonrungsiman S, Ruktanonchai UR, Graham D, Namdee K. Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood–brain barrier penetration. Sci Rep. 2019;9(1):8278. doi:10.1038/s41598-019-44569-6
   PubMedGoogle Scholar
• Liu C, Su C. Design strategies and application progress of therapeutic exosomes. Theranostics. 2019;9(4):1015–1028. doi:10.7150/thno.30853
   PubMed Web of Science ®Google Scholar
• Sherif AY, Harisa GI, Alanazi FK, Youssof AME. Engineering of Exosomes: steps Towards Green Production of Drug Delivery System. Curr Drug Targets. 2019;20(15):1537–1549. doi:10.2174/1389450120666190715104100
   PubMedGoogle Scholar
• Xie Y, Chen Y, Zhang L, Ge W, Tang P. The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling. J Cell Mol Med. 2017;21(5):1033–1041. doi:10.1111/jcmm.13039
   PubMed Web of Science ®Google Scholar
• Cappariello A, Loftus A, Muraca M, Maurizi A, Rucci N, Teti A. Osteoblast-Derived Extracellular Vesicles Are Biological Tools for the Delivery of Active Molecules to Bone. J Bone Mineral Res. 2018;33(3):517–533.
   PubMed Web of Science ®Google Scholar
• Deng L, Wang Y, Peng Y, et al. Osteoblast-derived microvesicles: a novel mechanism for communication between osteoblasts and osteoclasts. Bone. 2015;79:37–42. doi:10.1016/j.bone.2015.05.022
   PubMed Web of Science ®Google Scholar
• Sun W, Zhao C, Li Y, et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discovery. 2016;2(1):16015. doi:10.1038/celldisc.2016.15
   PubMedGoogle Scholar
• Kobayashi-Sun J, Yamamori S, Kondo M, Kuroda J, Ikegame M, Suzuki N. Uptake of osteoblast-derived extracellular vesicles promotes the differentiation of osteoclasts in the zebrafish scale. Commun Biol. 2020;3(1):190. doi:10.1038/s42003-020-0925-1
   PubMed Web of Science ®Google Scholar
• Qin Y, Wang L, Gao Z, Chen G, Zhang C. Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo. Sci Rep. 2016;6(1):21961. doi:10.1038/srep21961
   PubMedGoogle Scholar
• Furuta T, Miyaki S, Ishitobi H, et al. Mesenchymal Stem Cell-Derived Exosomes Promote Fracture Healing in a Mouse Model. Stem Cells Translational Med. 2016;5(12):1620–1630. doi:10.5966/sctm.2015-0285
   PubMed Web of Science ®Google Scholar
• Zhao P, Xiao L, Peng J, Qian YQ, Huang CC. Exosomes derived from bone marrow mesenchymal stem cells improve osteoporosis through promoting osteoblast proliferation via MAPK pathway. Eur Rev Med Pharmacol Sci. 2018;22(12):3962–3970. doi:10.26355/eurrev_201806_15280
   PubMed Web of Science ®Google Scholar
• Qiu M. Bone marrow mesenchymal stem cells-derived exosomal microRNA-150-3p promotes osteoblast proliferation and differentiation in osteoporosis. Human Gene Therapy. 2021
   Google Scholar
• Chindamo G, Sapino S, Peira E, Chirio D, Gonzalez MC, Gallarate M. Bone Diseases: current Approach and Future Perspectives in Drug Delivery Systems for Bone Targeted Therapeutics. Nanomaterials. 2020;10(5):875. doi:10.3390/nano10050875
   Web of Science ®Google Scholar
• Farrell KB, Karpeisky A, Thamm DH, Zinnen S. Bisphosphonate conjugation for bone specific drug targeting. Bone Reports. 2018;9:47–60. doi:10.1016/j.bonr.2018.06.007
   PubMedGoogle Scholar
• Brown JP, Morin S, Leslie W, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60(4):324–333.
   PubMedGoogle Scholar
• Faienza MF, Chiarito M, D’amato G, et al. Monoclonal antibodies for treating osteoporosis. Expert Opin Biol Ther. 2018;18(2):149–157. doi:10.1080/14712598.2018.1401607
   PubMed Web of Science ®Google Scholar
• Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008;6(1):24–30. doi:10.1007/s11914-008-0005-9
   PubMedGoogle Scholar
• Cosman F, Nieves JW, Dempster DW. Treatment Sequence Matters: anabolic and Antiresorptive Therapy for Osteoporosis. J Bone Mineral Res. 2017;32(2):198–202. doi:10.1002/jbmr.3051
   PubMed Web of Science ®Google Scholar
• Saikali Z, Singh G. Doxycycline and other tetracyclines in the treatment of bone metastasis. Anti-Cancer Drugs. 2003;14(10):773–778. doi:10.1097/00001813-200311000-00001
   PubMedGoogle Scholar
• Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5(1):21–26. doi:10.1200/JCO.1987.5.1.21
   PubMed Web of Science ®Google Scholar
• Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop. 2006;30(6):445–451. doi:10.1007/s00264-006-0192-x
   PubMed Web of Science ®Google Scholar
• Notelovitz M. Estrogen Therapy and Osteoporosis: principles & Practice. Am J Med Sci. 1997;313(1):2–12. doi:10.1097/00000441-199701000-00002
   PubMedGoogle Scholar
• Ganesan K, Roane D. Bisphosphonate. Treasure Island (FL): StatPearls Publishing; 2019.
   Google Scholar
• Favus MJ. Bisphosphonates for Osteoporosis. N Eng J Med. 2010;363(21):2027–2035. doi:10.1056/NEJMct1004903
   PubMed Web of Science ®Google Scholar
• Watts NB. Erratum. J Clin Endocrinol Metab. 2010;95(7):3565. doi:10.1210/jcem.95.7.9997
   Google Scholar
• Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J clin oncol. 2005;23(32):8219–8224. doi:10.1200/JCO.2005.02.9579
   PubMedGoogle Scholar
• Pfannkuchen N, Meckel M, Bergmann R, et al. Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases. Pharmaceuticals. 2017;10(2):45. doi:10.3390/ph10020045
   Google Scholar
• Wu VM, Mickens J, Uskoković V. Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma. ACS Appl Mater Interfaces. 2017;9(31):25887–25904. doi:10.1021/acsami.7b08108
   PubMedGoogle Scholar
• Inoue R, Matsuki N-A, Jing G. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol. 2005;146(5):633–641. doi:10.1038/sj.bjp.0706373
   PubMedGoogle Scholar
• Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85(6):1052–1062. doi:10.1111/bcp.13867
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(S12):2961–2978.
   PubMedGoogle Scholar
• Tanaka Y, Iwasaki M, Murata-Hirai K, et al. Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. Sci Rep. 2017;7(1):5987. doi:10.1038/s41598-017-05553-0
   PubMed Web of Science ®Google Scholar
• Heymann D, Ory B, Gouin F, Green JR, Rédini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med. 2004;10(7):337–343. doi:10.1016/j.molmed.2004.05.007
   PubMedGoogle Scholar
• Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009;7(1):18–22. doi:10.1007/s11914-009-0004-5
   PubMedGoogle Scholar
• Moen MD, Keam SJ. Denosumab. Drugs Aging. 2011;28(1):63–82. doi:10.2165/11203300-000000000-00000
   PubMedGoogle Scholar
• Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng J Med. 2009;361(8):756–765. doi:10.1056/NEJMoa0809493
   PubMed Web of Science ®Google Scholar
• Anandarajah AP, Schwarz EM. Anti-RANKL therapy for inflammatory bone disorders: mechanisms and potential clinical applications. J Cell Biochem. 2006;97(2):226–232.
   PubMedGoogle Scholar
• Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–692. doi:10.1016/j.bone.2010.11.020
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective Clin Trial. 2019;34(12):2220–2228.
   Google Scholar
• Matuoka JY, Kahn JG, Secoli SR. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. Eur J Health Economics. 2019;20(4):487–499. doi:10.1007/s10198-018-1011-1
   PubMedGoogle Scholar
• Perrin DD. Binding of Tetracyclines to Bone. Nature. 1965;208(5012):787–788. doi:10.1038/208787a0
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim J, Lee H, et al. Tetracycline Analogs Inhibit Osteoclast Differentiation by Suppressing MMP-9-Mediated Histone H3 Cleavage. J Cell Biochem. 2019;20(16):4038.
   Google Scholar
• Hochdörffer K, Abu Ajaj K, Schäfer-Obodozie C, Kratz F. Development of Novel Bisphosphonate Prodrugs of Doxorubicin for Targeting Bone Metastases That Are Cleaved pH Dependently or by Cathepsin B: synthesis, Cleavage Properties, and Binding Properties to Hydroxyapatite As Well As Bone Matrix. J Med Chem. 2012;55(17):7502–7515. doi:10.1021/jm300493m
   PubMedGoogle Scholar
• Ye W-L, Zhao Y-P, Li H-Q. Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer. Sci Rep. 2015;5(1):14614. doi:10.1038/srep14614
   PubMedGoogle Scholar
• Chun R, Kurzman ID, Couto CG, Klausner J, Henry C, MacEwen EG. Cisplatin and Doxorubicin Combination Chemotherapy for the Treatment of Canine Osteosarcoma: a Pilot Study. J Veterinary Internal Med. 2000;14(5):495–498. doi:10.1892/0891-6640(2000)014<0495:cadccf>2.3.co;2
   PubMedGoogle Scholar
• Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005;37(1):74–86. doi:10.1016/j.bone.2005.02.020
   PubMedGoogle Scholar
• Cassano WF, Graham-Pole J, Dickson N. Etoposide, cyclophosphamide, cisplatin, and doxorubicin as neoadjuvant chemotherapy for osteosarcoma. Cancer. 1991;68(9):1899–1902. doi:10.1002/1097-0142(19911101)68:9<1899::aid-cncr2820680909>3.0.co;2-x
   PubMedGoogle Scholar
• Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73(1):106–114. doi:10.1111/j.1365-2125.2011.04054.x
   PubMed Web of Science ®Google Scholar
• Joseph DL, Sahitya D, Jiaqiang Q, et al. Future Therapies for Human Osteosarcoma. Curr Cancer Ther Rev. 2013;9(1):55–77. doi:10.2174/1573394711309010006
   PubMedGoogle Scholar
• Ma H, He C, Cheng Y, et al. Localized Co-delivery of Doxorubicin, Cisplatin, and Methotrexate by Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment. ACS Appl Mater Interfaces. 2015;7(49):27040–27048. doi:10.1021/acsami.5b09112
   PubMed Web of Science ®Google Scholar
• Ferrari S, Serra M. An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 2015;16(18):2727–2736. doi:10.1517/14656566.2015.1102226
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis. Drugs Aging. 2007;24(5):361–379. doi:10.2165/00002512-200724050-00002
   PubMed Web of Science ®Google Scholar
• Peng L, Luo Q, Lu H. Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis. J Cell Biochem. 2017;96(49):e8659.
   Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial. J Bone Mineral Res. 2008;23(12):1923–1934.
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Nuti R. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin Interv Aging. 2010;5:19–29. doi:10.2147/CIA.S6083
   PubMed Web of Science ®Google Scholar
• Nelson ER, Wardell SE, McDonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis. Bone. 2013;53(1):42–50. doi:10.1016/j.bone.2012.11.011
   PubMed Web of Science ®Google Scholar
• Watts NB, Diab DL. Long-Term Use of Bisphosphonates in Osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1555–1565. doi:10.1210/jc.2009-1947
   PubMed Web of Science ®Google Scholar
• Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for Osteoporosis — where Do We Go from Here? N Eng J Med. 2012;366(22):2048–2051. doi:10.1056/NEJMp1202619
   PubMed Web of Science ®Google Scholar
• Compston J. Practical guidance for the use of bisphosphonates in osteoporosis. Bone. 2020;136:115330. doi:10.1016/j.bone.2020.115330
   PubMedGoogle Scholar
• Domschke C, Schuetz F. Side Effects of Bone-Targeted Therapies in Advanced Breast Cancer. Breast Care. 2014;9(5):332–336. doi:10.1159/000368844
   PubMedGoogle Scholar
• Vannala V, Palaian S, Shankar P. Therapeutic dimensions of bisphosphonates: a clinical update. Int J Preventive Med. 2020;11(1):166. doi:10.4103/ijpvm.IJPVM_33_19
   PubMedGoogle Scholar
• Cheng H, Chawla A, Yang Y, et al. Development of nanomaterials for bone-targeted drug delivery. Drug Discov Today. 2017;22(9):1336–1350. doi:10.1016/j.drudis.2017.04.021
   PubMed Web of Science ®Google Scholar
• Tran N, Pareta RA, Taylor E, Webster TJ. Iron oxide nanoparticles: novel drug delivery materials for treating bone diseases. Adv Mater Res. 2010;89–91:411–418. doi:10.4028/www.scientific.net/AMR.89-91.411
   Google Scholar
• Wang D, Miller S, Sima M, Kopečková P, Kopeček J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem. 2003;14(5):853–859. doi:10.1021/bc034090j
   PubMedGoogle Scholar
• Sun W, Ge K, Jin Y, et al. Bone-targeted nanoplatform combining zoledronate and photothermal therapy to treat breast cancer bone metastasis. ACS Nano. 2019;13(7):7556–7567. doi:10.1021/acsnano.9b00097
   PubMed Web of Science ®Google Scholar
• Peng Z, Miyanji EH, Zhou Y, et al. Carbon dots: promising biomaterials for bone-specific imaging and drug delivery. Nanoscale. 2017;9(44):17533–17543. doi:10.1039/C7NR05731H
   PubMed Web of Science ®Google Scholar
• Medina-Cruz D, Mostafavi E, Vernet-Crua A, et al. Green nanotechnology-based drug delivery systems for osteogenic disorders. Expert Opin Drug Deliv. 2020;17(3):341–356. doi:10.1080/17425247.2020.1727441
   PubMed Web of Science ®Google Scholar
• Wang F, Chen L, Zhang R, Chen Z, Zhu L. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer. J Controlled Release. 2014;196:222–233. doi:10.1016/j.jconrel.2014.10.012
   PubMed Web of Science ®Google Scholar
• Marra M, Salzano G, Leonetti C, et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv. 2012;30(1):302–309. doi:10.1016/j.biotechadv.2011.06.018
   PubMed Web of Science ®Google Scholar
• Martínez-Carmona M, Lozano D, Colilla M, Vallet-Regí M. Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment. Acta Biomaterialia. 2018;65:393–404. doi:10.1016/j.actbio.2017.11.007
   PubMed Web of Science ®Google Scholar
• Jawahar N, Meyyanathan S. Polymeric nanoparticles for drug delivery and targeting: a comprehensive review. J Bone Mineral Res. 2012;1(4):217–223.
   Google Scholar
• Rai R, Alwani S, Badea I. Polymeric Nanoparticles in Gene Therapy: new Avenues of Design and Optimization for Delivery Applications. J Bone Mineral Res. 2019;11(4):745.
   Google Scholar
• Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng. 2016;60:569–578. doi:10.1016/j.msec.2015.11.067
   Google Scholar
• Son J, Yang SM, Yi G, et al. Folate-modified PLGA nanoparticles for tumor-targeted delivery of pheophorbide a in vivo. Biochem Biophys Res Commun. 2018;498(3):523–528. doi:10.1016/j.bbrc.2018.03.013
   PubMed Web of Science ®Google Scholar
• Dangi R, Hurkat P, Jain A, et al. Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles. J Microencapsul. 2014;31(5):479–487. doi:10.3109/02652048.2013.879929
   PubMed Web of Science ®Google Scholar
• Salmaso S, Caliceti P. Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers. J Drug Deliv. 2013;2013:374252. doi:10.1155/2013/374252
   PubMedGoogle Scholar
• Wang B, Yu X-C, Xu S-F, Xu M. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. J Nanobiotechnology. 2015;13(1):22. doi:10.1186/s12951-015-0086-4
   PubMed Web of Science ®Google Scholar
• Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9(11):1319–1323. doi:10.1517/17425247.2012.720969
   PubMed Web of Science ®Google Scholar
• Elsabahy M, Perron M-È, Bertrand N. Solubilization of Docetaxel in Poly(ethylene oxide)-block-poly(butylene/styrene oxide) Micelles. Biomacromolecules. 2007;8(7):2250–2257. doi:10.1021/bm070226v
   PubMedGoogle Scholar
• Chen Y, Zhang YX, Wu ZF, et al. Biodegradable poly(ethylene glycol)–poly(ε-carprolactone) polymeric micelles with different tailored topological amphiphilies for doxorubicin (DOX) drug delivery. RSC Adv. 2016;6(63):58160–58172. doi:10.1039/C6RA06040D
   Google Scholar
• Liu T, Romanova S, Wang S, et al. Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis. Mol Pharm. 2019;16(7):2872–2883. doi:10.1021/acs.molpharmaceut.8b01343
   PubMedGoogle Scholar
• Kulthe SS, Choudhari YM, Inamdar NN, Mourya V. Polymeric micelles: authoritative aspects for drug delivery. Designed Monomers Polymers. 2012;15(5):465–521. doi:10.1080/1385772X.2012.688328
   Web of Science ®Google Scholar
• Tomalia DA, Fréchet JMJ. Discovery of dendrimers and dendritic polymers: a brief historical perspective. J Bone Mineral Res. 2002;40(16):2719–2728.
   Google Scholar
• Patel H, Patel P. Dendrimer applications–a review. Chem Commun. 2013;4(2):454–463.
   Google Scholar
• Bo J, Jing Z, Yanhua L, et al. Dual-targeting Janus Dendrimer Based Peptides for Bone Cancer: synthesis and Preliminary Biological Evaluation. Lett Org Chem. 2013;10(8):594–601. doi:10.2174/15701786113109990024
   Google Scholar
• Pasut G, Veronese FM. Polymer–drug conjugation, recent achievements and general strategies. Prog Polym Sci. 2007;32(8):933–961. doi:10.1016/j.progpolymsci.2007.05.008
   Google Scholar
• Kwon S, Singh RK, Perez RA, Abou Neel EA, Kim H-W, Chrzanowski W. Silica-based mesoporous nanoparticles for controlled drug delivery. J Tissue Eng. 2013;4:2041731413503357.
   Google Scholar
• Lin Y-S, Abadeer N, Haynes CL. Stability of small mesoporous silica nanoparticles in biological media. Chem Commun. 2011;47(1):532–534. doi:10.1039/C0CC02923H
   PubMed Web of Science ®Google Scholar
• Ma X, Zhao Y, Ng KW, Zhao Y. Integrated Hollow Mesoporous Silica Nanoparticles for Target Drug/siRNA Co-Delivery. Chemistry. 2013;19(46):15593–15603. doi:10.1002/chem.201302736
   PubMedGoogle Scholar
• Pasqua L, De Napoli IE, De Santo M, et al. Mesoporous silica-based hybrid materials for bone-specific drug delivery. Nanoscale Adv. 2019;1(8):3269–3278. doi:10.1039/C9NA00249A
   PubMedGoogle Scholar
• Shahbazi M-A, Herranz B, Santos HA. Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter. 2012;2(4):296–312. doi:10.4161/biom.22347
   PubMedGoogle Scholar
• Piao Y, Kim J, Na HB, et al. Wrap–bake–peel process for nanostructural transformation from β-FeOOH nanorods to biocompatible iron oxide nanocapsules. Nat Mater. 2008;7(3):242–247. doi:10.1038/nmat2118
   PubMedGoogle Scholar
• Kandasamy R, Kandasamy R. A novel single step synthesis and surface functionalization of iron oxide magnetic nanoparticles and thereof for the copper removal from pigment industry effluent. Sep Purif Technol. 2017;188:458–467. doi:10.1016/j.seppur.2017.07.059
   Google Scholar
• Hu FX, Neoh KG, Kang ET. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials. 2006;27(33):5725–5733. doi:10.1016/j.biomaterials.2006.07.014
   PubMed Web of Science ®Google Scholar
• Sharma P, Rana S, Barick KC, Kumar C, Salunke HG, Hassan PA. Biocompatible phosphate anchored Fe3O4 nanocarriers for drug delivery and hyperthermia. New J Chem. 2014;38(11):5500–5508. doi:10.1039/C4NJ01431F
   Google Scholar
• Gul S, Khan SB, Rehman IU, Khan MA, Khan MI, Comprehensive A. Review of Magnetic Nanomaterials Modern Day Theranostics. J Tissue Eng. 2019;6:179.
   Google Scholar
• Çağdaş M, Sezer AD, Bucak S. Liposomes as Potential Drug Carrier Systems for Drug Delivery. Application Nanotechnol Drug Delivery. 2014.
   Google Scholar
• Boakye CHA, Patel K, Singh M. Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers. Int J Pharm. 2015;489(1):106–116. doi:10.1016/j.ijpharm.2015.04.059
   PubMedGoogle Scholar
• Gu Q, Yang H, Shi Q. Macrophages and bone inflammation. J Orthopaedic Translation. 2017;10:86–93. doi:10.1016/j.jot.2017.05.002
   PubMed Web of Science ®Google Scholar
• Neog MK, Rasool M. Targeted delivery of p-coumaric acid encapsulated mannosylated liposomes to the synovial macrophages inhibits osteoclast formation and bone resorption in the rheumatoid arthritis animal model. Eur J Pharmaceutics Biopharmaceutics. 2018;133:162–175. doi:10.1016/j.ejpb.2018.10.010
   PubMed Web of Science ®Google Scholar
• Olusanya TOB, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA. Liposomal Drug Delivery Systems and Anticancer Drugs. Molecules. 2018;23(4):907.
   PubMed Web of Science ®Google Scholar
• Gheinani AH, Vögeli M, Baumgartner U, et al. Improved isolation strategies to increase the yield and purity of human urinary exosomes for biomarker discovery. Sci Rep. 2018;8(1):3945. doi:10.1038/s41598-018-22142-x
   PubMedGoogle Scholar
• Dash P, Piras AM, Dash M. Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy. J Controlled Release. 2020;327:546–570. doi:10.1016/j.jconrel.2020.09.012
   PubMed Web of Science ®Google Scholar
• Luk BT, Zhang L. Cell membrane-camouflaged nanoparticles for drug delivery. J Controlled Release. 2015;220:600–607. doi:10.1016/j.jconrel.2015.07.019
   PubMed Web of Science ®Google Scholar
• Li Z, Hu S, Cheng K. Platelets and their biomimetics for regenerative medicine and cancer therapies. J Mater Chem B. 2018;6(45):7354–7365. doi:10.1039/C8TB02301H
   PubMed Web of Science ®Google Scholar
• Fang RH, Hu C-MJ, Luk BT, et al. Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery. Nano Lett. 2014;14(4):2181–2188. doi:10.1021/nl500618u
   PubMed Web of Science ®Google Scholar
• Fan Z, Li PY, Deng J, Bady SC, Cheng H. Cell membrane coating for reducing nanoparticle-induced inflammatory responses to scaffold constructs. Nano Res. 2018;11(10):5573–5583. doi:10.1007/s12274-018-2084-y
   PubMed Web of Science ®Google Scholar
• György B, Szabó TG, Pásztói M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68(16):2667–2688.
   PubMed Web of Science ®Google Scholar
• Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–579. doi:10.1038/nri855
   PubMed Web of Science ®Google Scholar
• Gulei D, Irimie AI, Cojocneanu-Petric R, Schultze JL, Berindan-Neagoe I. Exosomes-Small Players, Big Sound. Bioconjug Chem. 2018;29(3):635–648. doi:10.1021/acs.bioconjchem.8b00003
   PubMedGoogle Scholar
• Keerthikumar S, Chisanga D, Ariyaratne D, et al. ExoCarta: a Web-Based Compendium of Exosomal Cargo. J Mol Biol. 2016;428(4):688–692. doi:10.1016/j.jmb.2015.09.019
   PubMed Web of Science ®Google Scholar
• Pathan M, Fonseka P, Chitti SV, et al. Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2018;47(D1):D516–D519. doi:10.1093/nar/gky1029
   Google Scholar
• Qureshi MZ. Introducing Vesiclepedia. Nat Methods. 2013;10(3):194. doi:10.1038/nmeth.2384
   Google Scholar
• Boriachek K, Islam MN, Möller A, et al. Biological Functions and Current Advances in Isolation and Detection Strategies for Exosome Nanovesicles. Small. 2017;14(6):1702153. doi:10.1002/smll.201702153
   Google Scholar
• Mathivanan S, Fahner CJ, Reid GE, Simpson RJ. ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 2012;40(Database issue):D1241–D1244. doi:10.1093/nar/gkr828
   PubMed Web of Science ®Google Scholar
• Farooqi AA, Desai NN, Qureshi MZ, et al. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol Adv. 2018;36(1):328–334. doi:10.1016/j.biotechadv.2017.12.010
   PubMed Web of Science ®Google Scholar
• Yokoi A, Yoshioka Y, Yamamoto Y, et al. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nat Commun. 2017;8(1):14470. doi:10.1038/ncomms14470
   PubMedGoogle Scholar
• Lv -L-L, Feng Y, Wu M, et al. Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. Cell Death Differ. 2020;27(1):210–226. doi:10.1038/s41418-019-0349-y
   PubMed Web of Science ®Google Scholar
• Wu M, Ouyang Y, Wang Z, et al. Isolation of exosomes from whole blood by integrating acoustics and microfluidics. Proce National Acad Sci. 2017;114(40):10584. doi:10.1073/pnas.1709210114
   PubMed Web of Science ®Google Scholar
• El Andaloussi S, Mäger I, Breakefield XO, Wood MJA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12(5):347–357. doi:10.1038/nrd3978
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X-L, Chen L, et al. Epigenetic mechanisms of bone regeneration and homeostasis. Prog Biophys Mol Biol. 2016;122(2):85–92. doi:10.1016/j.pbiomolbio.2016.01.005
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of Bone Metastasis. N Eng J Med. 2004;350(16):1655–1664. doi:10.1056/NEJMra030831
   PubMed Web of Science ®Google Scholar
• Yoshiko Y, Minamizaki T. Emerging roles of microRNAs as extracellular vesicle cargo secreted from osteoblasts. J Oral Biosci. 2020;62(3):228–234. doi:10.1016/j.job.2020.05.006
   PubMed Web of Science ®Google Scholar
• Cui Y, Luan J, Li H, Zhou X, Han J. Exosomes derived from mineralizing osteoblasts promote ST2 cell osteogenic differentiation by alteration of microRNA expression. FEBS Lett. 2016;590(1):185–192. doi:10.1002/1873-3468.12024
   PubMed Web of Science ®Google Scholar
• Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139–146. doi:10.1016/j.abb.2008.03.018
   PubMed Web of Science ®Google Scholar
• Sojod B, Chateau D, Mueller CG, et al. RANK/RANKL/OPG Signalization Implication in Periodontitis: new Evidence from a RANK Transgenic Mouse Model. Frontiers in Physiology. 2017;8(338). doi:10.3389/fphys.2017.00338
   PubMedGoogle Scholar
• Jimi E. The role of osteoclastic bone resorption on bone remodeling. Clin Calcium. 2017;27(12):1689–1695.
   PubMedGoogle Scholar
• Huynh N, VonMoss L, Smith D, et al. Characterization of Regulatory Extracellular Vesicles from Osteoclasts. J Dent Res. 2016;95(6):673–679. doi:10.1177/0022034516633189
   PubMed Web of Science ®Google Scholar
• Gao M, Gao W, Papadimitriou JM, Zhang C, Gao J, Zheng M. Exosomes-the enigmatic regulators of bone homeostasis. Bone Res. 2018;6:36. doi:10.1038/s41413-018-0039-2
   PubMed Web of Science ®Google Scholar
• Liu M, Sun Y, Zhang Q. Emerging Role of Extracellular Vesicles in Bone Remodeling. J Dent Res. 2018;97(8):859–868. doi:10.1177/0022034518764411
   PubMed Web of Science ®Google Scholar
• Cappariello A, Loftus A, Muraca M, Maurizi A, Rucci N, Teti A. Osteoblast-Derived Extracellular Vesicles Are Biological Tools for the Delivery of Active Molecules to Bone. J Bone Mineral Res. 2018;33(3):517–533. doi:10.1002/jbmr.3332
   PubMed Web of Science ®Google Scholar
• Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: an updated review. Int J Pharm Investig. 2012;2(1):2–11. doi:10.4103/2230-973X.96920
   PubMedGoogle Scholar
• Tan ML, Choong PFM, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides. 2010;31(1):184–193. doi:10.1016/j.peptides.2009.10.002
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Liposomes in Drug Delivery: how It All Happened. Pharmaceutics. 2016;8(2):19. doi:10.3390/pharmaceutics8020019
   PubMed Web of Science ®Google Scholar
• El-Hammadi MM, Arias JL. An update on liposomes in drug delivery: a patent review (2014-2018). Expert Opin Ther Pat. 2019;29(11):891–907. doi:10.1080/13543776.2019.1679767
   PubMed Web of Science ®Google Scholar
• Mao J, Li Y, Wu T, et al. Responsive Prodrug-Based Polymeric Micelles for Drug Delivery. ACS Appl Mater Interfaces. 2016;8(27):17109–17117. doi:10.1021/acsami.6b04247
   PubMed Web of Science ®Google Scholar
• Janas C, Mostaphaoui Z, Schmiederer L, Bauer J, Wacker MG. Novel polymeric micelles for drug delivery: material characterization and formulation screening. Int J Pharm. 2016;509(1):197–207. doi:10.1016/j.ijpharm.2016.05.029
   PubMedGoogle Scholar
• Sur S, Rathore A, Dave V, Reddy KR, Chouhan RS, Sadhu V. Recent developments in functionalized polymer nanoparticles for efficient drug delivery system. Nano Structures Nano Objects. 2019;20:100397. doi:10.1016/j.nanoso.2019.100397
   Google Scholar
• Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres M. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71. doi:10.1186/s12951-018-0392-8
   PubMed Web of Science ®Google Scholar
• Elsharkasy OM, Nordin JZ, Hagey DW, et al. Extracellular vesicles as drug delivery systems: why and how? Adv Drug Deliv Rev. 2020;159:332–343. doi:10.1016/j.addr.2020.04.004
   PubMed Web of Science ®Google Scholar
• Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106:148–156. doi:10.1016/j.addr.2016.02.006
   PubMed Web of Science ®Google Scholar
• Gudbergsson JM, Jønsson K, Simonsen JB, Johnsen KB. Systematic review of targeted extracellular vesicles for drug delivery – considerations on methodological and biological heterogeneity. J Controlled Release. 2019;306:108–120. doi:10.1016/j.jconrel.2019.06.006
   PubMed Web of Science ®Google Scholar
• Huang D, Wu D. Biodegradable dendrimers for drug delivery. Mater Sci Eng. 2018;90:713–727. doi:10.1016/j.msec.2018.03.002
   Google Scholar
• Wang Y, Luo Y, Zhao Q, Wang Z, Xu Z, Jia X. An Enzyme-Responsive Nanogel Carrier Based on PAMAM Dendrimers for Drug Delivery. ACS Appl Mater Interfaces. 2016;8(31):19899–19906. doi:10.1021/acsami.6b05567
   PubMed Web of Science ®Google Scholar
• Peng H, Ji W, Zhao R, et al. Exosome: a significant nano-scale drug delivery carrier. J Mater Chem B. 2020;8(34):7591–7608. doi:10.1039/D0TB01499K
   PubMed Web of Science ®Google Scholar
• Maia J, Caja S, Strano Moraes MC, Couto N, Costa-Silva B. Exosome-based cell-cell communication in the tumor microenvironment. Front Cell Dev Biol. 2018;6(18). doi:10.3389/fcell.2018.00018
   PubMedGoogle Scholar
• Jiang X-C, Gao J-Q. Exosomes as novel bio-carriers for gene and drug delivery. Int J Pharm. 2017;521(1):167–175. doi:10.1016/j.ijpharm.2017.02.038
   PubMedGoogle Scholar
• Ohno S-I, Takanashi M, Sudo K. Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. Mol Therapy. 2013;21(1):185–191. doi:10.1038/mt.2012.180
   PubMed Web of Science ®Google Scholar
• Sun D, Zhuang X, Xiang X, et al. Drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Therapy. 2010;18(9):1606–1614. doi:10.1038/mt.2010.105
   PubMed Web of Science ®Google Scholar
• Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Controlled Release. 2015;207:18–30. doi:10.1016/j.jconrel.2015.03.033
   PubMed Web of Science ®Google Scholar
• Aqil F, Munagala R, Jeyabalan J, et al. Milk exosomes - Natural nanoparticles for siRNA delivery. Cancer Lett. 2019;449:186–195. doi:10.1016/j.canlet.2019.02.011
   PubMed Web of Science ®Google Scholar
• Morishita M, Takahashi Y, Nishikawa M, Takakura Y. Pharmacokinetics of Exosomes—An Important Factor for Elucidating the Biological Roles of Exosomes and for the Development of Exosome-Based Therapeutics. J Pharm Sci. 2017;106(9):2265–2269. doi:10.1016/j.xphs.2017.02.030
   PubMed Web of Science ®Google Scholar
• Tian T, Zhang H-X, He C-P, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018;150:137–149. doi:10.1016/j.biomaterials.2017.10.012
   PubMed Web of Science ®Google Scholar
• Salunkhe S, Basak M, Chitkara D, Mittal A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance. J Controlled Release. 2020;326:599–614. doi:10.1016/j.jconrel.2020.07.042
   PubMed Web of Science ®Google Scholar
• Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017;38(6):754–763. doi:10.1038/aps.2017.12
   PubMed Web of Science ®Google Scholar
• Zhuang X, Xiang X, Grizzle W, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Therapy. 2011;19(10):1769–1779. doi:10.1038/mt.2011.164
   PubMed Web of Science ®Google Scholar
• Qu M, Lin Q, Huang L, et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease. J Controlled Release. 2018;287:156–166. doi:10.1016/j.jconrel.2018.08.035
   PubMed Web of Science ®Google Scholar
• Bunggulawa EJ, Wang W, Yin T, et al. Recent advancements in the use of exosomes as drug delivery systems. J Nanobiotechnology. 2018;16(1):81. doi:10.1186/s12951-018-0403-9
   PubMed Web of Science ®Google Scholar
• Song H, Li X, Zhao Z, et al. Reversal of osteoporotic activity by endothelial cell-secreted bone targeting and biocompatible exosomes. Nano Lett. 2019;19(5):3040–3048. doi:10.1021/acs.nanolett.9b00287
   PubMed Web of Science ®Google Scholar
• Mehryab F, Rabbani S, Shahhosseini S, et al. Exosomes as a next-generation drug delivery system: an update on drug loading approaches, characterization, and clinical application challenges. Acta Biomaterialia. 2020;113:42–62. doi:10.1016/j.actbio.2020.06.036
   PubMed Web of Science ®Google Scholar
• Wei H, Chen J, Wang S, et al. Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro. Int J Nanomedicine. 2019;14:8603–8610. doi:10.2147/IJN.S218988
   PubMed Web of Science ®Google Scholar
• Luo Z-W, Li F-X-Z, Liu Y-W, et al. Aptamer-functionalized exosomes from bone marrow stromal cells target bone to promote bone regeneration. Nanoscale. 2019;11(43):20884–20892. doi:10.1039/C9NR02791B
   PubMed Web of Science ®Google Scholar
• Lin Q, Qu M, Zhou B, et al. Exosome-like nanoplatform modified with targeting ligand improves anti-cancer and anti-inflammation effects of imperialine. J Controlled Release. 2019;311:104–116. doi:10.1016/j.jconrel.2019.08.037
   PubMedGoogle Scholar
• Yuan D, Zhao Y, Banks WA, et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials. 2017;142:1–12. doi:10.1016/j.biomaterials.2017.07.011
   PubMed Web of Science ®Google Scholar
• Yan F, Zhong Z, Wang Y, et al. Exosome-based biomimetic nanoparticles targeted to inflamed joints for enhanced treatment of rheumatoid arthritis. J Nanobiotechnology. 2020;18(1):115. doi:10.1186/s12951-020-00675-6
   PubMed Web of Science ®Google Scholar
• Li X, Corbett AL, Taatizadeh E, et al. Challenges and opportunities in exosome research—Perspectives from biology, engineering, and cancer therapy. APL Bioeng. 2019;3(1):011503.
   PubMed Web of Science ®Google Scholar
• Ludwig N, Whiteside TL, Reichert TE. Challenges in Exosome Isolation and Analysis in Health and Disease. Int J Mol Sci. 2019;20(19):4684.
   PubMed Web of Science ®Google Scholar
• Yang D, Zhang W, Zhang H, et al. Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics. 2020;10(8):3684–3707. doi:10.7150/thno.41580
   PubMed Web of Science ®Google Scholar
• King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2012;12(1):421. doi:10.1186/1471-2407-12-421
   PubMed Web of Science ®Google Scholar
• Théry C, Amigorena S, Raposo G, Clayton A. Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids. Int J Mol Sci. 2006;30(1):3.22.1–3.22.29.
   Google Scholar
• Lobb RJ, Becker M, Wen SW, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracellular Vesicles. 2015;4:27031. doi:10.3402/jev.v4.27031
   PubMed Web of Science ®Google Scholar
• Gupta S, Rawat S, Arora V, et al. An improvised one-step sucrose cushion ultracentrifugation method for exosome isolation from culture supernatants of mesenchymal stem cells. Stem Cell Res Ther. 2018;9(1):180. doi:10.1186/s13287-018-0923-0
   PubMedGoogle Scholar
• Pedersen KW, Kierulf B, Manger I, Oksvold MP, Li M. Direct Isolation of Exosomes from Cell Culture: simplifying Methods for Exosome Enrichment and Analysis. Int J Mol Sci. 2015;6.
   PubMedGoogle Scholar
• Karttunen J, Heiskanen M, Navarro-Ferrandis V, et al. Precipitation-based extracellular vesicle isolation from rat plasma co-precipitate vesicle-free microRNAs. J Extracellular Vesicles. 2019;8(1):1555410. doi:10.1080/20013078.2018.1555410
   PubMedGoogle Scholar
• Böing AN, van der Pol E, Grootemaat AE, Coumans FAW, Sturk A, Nieuwland R. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracellular Vesicles. 2014;3(1):23430. doi:10.3402/jev.v3.23430
   PubMedGoogle Scholar
• Gholizadeh S, Shehata Draz M, Zarghooni M, et al. Microfluidic approaches for isolation, detection, and characterization of extracellular vesicles: current status and future directions. Biosens Bioelectron. 2017;91:588–605. doi:10.1016/j.bios.2016.12.062
   PubMed Web of Science ®Google Scholar
• Contreras-Naranjo JC, Wu H-J, Ugaz VM. Microfluidics for exosome isolation and analysis: enabling liquid biopsy for personalized medicine. Lab Chip. 2017;17(21):3558–3577. doi:10.1039/C7LC00592J
   PubMed Web of Science ®Google Scholar
• Konoshenko MY, Lekchnov EA, Vlassov AV, Laktionov PP. Isolation of Extracellular Vesicles: general Methodologies and Latest Trends. Biomed Res Int. 2018;2018:8545347. doi:10.1155/2018/8545347
   PubMed Web of Science ®Google Scholar
• Zhao X, Wu D, Ma X, Wang J, Hou W, Zhang W. Exosomes as drug carriers for cancer therapy and challenges regarding exosome uptake. Biomed Pharmacotherapy. 2020;128:110237. doi:10.1016/j.biopha.2020.110237
   PubMed Web of Science ®Google Scholar
• Buschow SI, van Balkom BWM, Aalberts M, Heck AJR, Wauben M, Stoorvogel W. MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. Immunology Cell Biol. 2010;88(8):851–856.
   PubMed Web of Science ®Google Scholar
• Denzer K, van Eijk M, Kleijmeer MJ, et al. Cells Carry MHC Class II-Expressing Microvesicles at Their Surface. J Immunol. 2000;165(3):1259–1265. doi:10.4049/jimmunol.165.3.1259
   PubMed Web of Science ®Google Scholar
• Quah BJC, O’Neill HC. The immunogenicity of dendritic cell-derived exosomes. Blood Cells Mol Dis. 2005;35(2):94–110. doi:10.1016/j.bcmd.2005.05.002
   PubMed Web of Science ®Google Scholar
• Muhsin-Sharafaldine M-R, Saunderson SC, Dunn AC, Faed JM, Kleffmann T, McLellan AD. Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. Oncotarget. 2016;7(35):56279–56294. doi:10.18632/oncotarget.10783
   PubMedGoogle Scholar
• Van Niel G, Mallegol J, Bevilacqua C, et al. Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice. Gut. 2003;52(12):1690–1697. doi:10.1136/gut.52.12.1690
   PubMed Web of Science ®Google Scholar
• Gomari H, Forouzandeh Moghadam M, Soleimani M. Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle. Onco Targets Ther. 2018;11:5753–5762. doi:10.2147/OTT.S173110
   PubMed Web of Science ®Google Scholar
• Elkhoury K, Koçak P, Kang A, Arab-Tehrany E, Ellis Ward J, Shin SR. Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery. Immunology Cell Biol. 2020;12(9):849.
   Google Scholar
• Rayamajhi S, Aryal S. Surface functionalization strategies of extracellular vesicles. J Mater Chem B. 2020;8(21):4552–4569. doi:10.1039/D0TB00744G
   PubMedGoogle Scholar
• Sato YT, Umezaki K, Sawada S. Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep. 2016;6(1):21933. doi:10.1038/srep21933
   PubMed Web of Science ®Google Scholar
• Zhuang M, Chen X, Du D, et al. SPION decorated exosome delivery of TNF-α to cancer cell membranes through magnetism. Nanoscale. 2020;12(1):173–188. doi:10.1039/C9NR05865F
   PubMed Web of Science ®Google Scholar
• Conlan RS, Pisano S, Oliveira MI, Ferrari M, Mendes Pinto I. Exosomes as Reconfigurable Therapeutic Systems. Trends Mol Med. 2017;23(7):636–650. doi:10.1016/j.molmed.2017.05.003
   PubMed Web of Science ®Google Scholar
• Kooijmans SAA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine. 2012;7:1525–1541. doi:10.2147/IJN.S29661
   PubMed Web of Science ®Google Scholar
• Jang SC, Kim OY, Yoon CM, et al. Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors. ACS Nano. 2013;7(9):7698–7710. doi:10.1021/nn402232g
   PubMed Web of Science ®Google Scholar
• Pisano S, Pierini I, Gu J, et al. Immune (Cell) Derived Exosome Mimetics (IDEM) as a Treatment for Ovarian Cancer. Front Cell DevBiol. 2020;8(932). doi:10.3389/fcell.2020.553576
   Google Scholar
• Kalimuthu S, Gangadaran P, Rajendran RL, et al. Approach for loading anticancer drugs into mesenchymal stem cell-derived exosome mimetics for cancer therapy. Immunology Cell Biol. 2018;9:1116.
   Google Scholar
• Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. A comprehensive overview of exosomes as drug delivery vehicles — endogenous nanocarriers for targeted cancer therapy. Biochimica et Biophysica Acta. 2014;1846(1):75–87. doi:10.1016/j.bbcan.2014.04.005
   PubMed Web of Science ®Google Scholar
• Biver E, Thouverey C, Magne D, Caverzasio J. Crosstalk between tyrosine kinase receptors, GSK3 and BMP2 signaling during osteoblastic differentiation of human mesenchymal stem cells. Mol Cell Endocrinol. 2014;382(1):120–130. doi:10.1016/j.mce.2013.09.018
   PubMed Web of Science ®Google Scholar
• Rayamajhi S, Nguyen TDT, Marasini R, Aryal S. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. Acta Biomaterialia. 2019;94:482–494. doi:10.1016/j.actbio.2019.05.054
   PubMed Web of Science ®Google Scholar
• Lin Y, Wu J, Gu W, et al. Exosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. Advanced Sci. 2018;5(4):1700611.
   Web of Science ®Google Scholar
• Piffoux M, Silva AKA, Wilhelm C, Gazeau F, Tareste D. Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems. ACS Nano. 2018;12(7):6830–6842. doi:10.1021/acsnano.8b02053
   PubMed Web of Science ®Google Scholar
• Lv Q, Cheng L, Lu Y, et al. Thermosensitive Exosome–Liposome Hybrid Nanoparticle-Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer. Advanced Sci. 2020;7(18):2000515.
   Google Scholar
• Han Z, Lv W, Li Y, et al. Improving tumor targeting of exosomal membrane-coated polymeric nanoparticles by conjugation with aptamers. ACS Applied Bio Materials. 2020;3(5):2666–2673. doi:10.1021/acsabm.0c00181
   PubMedGoogle Scholar
• Sawada S-I, Sato YT, Kawasaki R. Nanogel hybrid assembly for exosome intracellular delivery: effects on endocytosis and fusion by exosome surface polymer engineering. Biomaterials Sci. 2020;8(2):619–630. doi:10.1039/C9BM01232J
   PubMed Web of Science ®Google Scholar
• Jo W, Jeong D, Kim J, et al. Microfluidic fabrication of cell-derived nanovesicles as endogenous RNA carriers. Lab Chip. 2014;14(7):1261–1269. doi:10.1039/C3LC50993A
   PubMed Web of Science ®Google Scholar
• Illes B, Hirschle P, Barnert S, Cauda V, Wuttke S, Engelke H. Exosome-coated metal–organic framework nanoparticles: an efficient drug delivery platform. Chem Mater. 2017;29(19):8042–8046. doi:10.1021/acs.chemmater.7b02358
   Google Scholar
• Zha Y, Lin T, Li Y, et al. Exosome-mimetics as an engineered gene-activated matrix induces in-situ vascularized osteogenesis. Biomaterials. 2020;247:119985. doi:10.1016/j.biomaterials.2020.119985
   PubMed Web of Science ®Google Scholar